Forever Labs will dedicate resources to continue pioneering stem cell research breakthroughs and accelerate brand development.
Founded in 2015, Forever Labs is transforming the healthcare industry by preserving healthy stem cells for future therapies that combat age-related diseases, as well as aging itself.
Its proprietary procedure involves a certified Forever Labs physician collecting one's mesenchymal stem cells (MSCs), which have the ability to stimulate tissues to grow and repair themselves when most needed.
After a brief outpatient procedure, the stem cells are cryogenically frozen and safely stored agnostically in an FDA-compliant clinical-grade biorepository until needed.
Forever Labs was created to preserve healthy stem cells to later rejuvenate one's MSC population to significantly delay the onset of those age-related diseases and extend a healthy lifespan.
argenx advances ARGX-119 to registrational study for congenital myasthenic syndromes
hVIVO supports Cidara Therapeutics' positive Phase 2b influenza study results
Sanofi's riliprubart receives orphan drug designation in Japan for CIDP
HUTCHMED gains China approval for ORPATHYS and TAGRISSO combination in lung cancer
Hikma Pharmaceuticals USA announces USD1bn of new US investment
UCB reports positive Phase 3 results for fenfluramine in CDKL5 deficiency disorder